Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them.

Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025.

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults with ulcerative colitis. As the first and only IL-23 inhibitor with a fully subcutaneous regimen, Tremfya achieved significant clinical remission and endoscopic improvement in Phase 3 trials. JNJ is also launching a head-to-head trial comparing Tremfya to AbbVie’s Skyrizi in Crohn’s disease, underscoring its commitment to expanding in immunology.

In Europe, Johnson & Johnson (NYSE:JNJ) reported progress for nipocalimab, an investigational FcRn blocker for antibody-positive generalized myasthenia gravis in both adults and adolescents. Pending European Commission approval, it could become the first treatment of its kind, supported by compelling late-stage trial data.

The business also expanded its oncology portfolio with FDA approval of a new drug delivery system for bladder cancer, offering patients a potential alternative to surgery and reinforcing its position in cancer innovation.

On the financial front, Johnson & Johnson (NYSE:JNJ)’s shares are up 20% year-to-date, boosted by pharmaceutical growth and easing legal risks compared to previous years. Still, the company continues to navigate ongoing talc-related litigation, with settlements and court proceedings drawing attention.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.